Nucleic Acid Aptamer Nucleic acid aptamers are single-stranded DNA or RNA (ssDNA or ssRNA) that are able to bind specifically to target molecules by folding to form a unique tertiary structure. TheRead More…
In a new study, researchers have identified a series of molecular interactions that may be key to stopping the spread of cancer cells. The new study identifies, for the first time, aRead More…
The human immune system’s most crucial element is the complement, and its two most essential subtypes are C3 and C4. Low levels of the two subtypes indicate that the immune system ofRead More…
On November 3, 2022, Iveric Bio announced that it had submitted the first part of the “rolling review” for the new drug application (NDA) of avacincaptad pegol (ACP, also known as Zimura)Read More…
Novartis recently announced that its new drug iptacopan has achieved positive results in a Phase 3 clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), with patients’ hemoglobin levels increasing significantlyRead More…
Myasthenia gravis (MG) is an autoimmune disease characterized by an acquired neuromuscular junction transmission disorder mediated by autoantibodies. MG patients are mainly characterized by fluctuating weakness and fatigue of skeletal muscles, withRead More…
In 2013, experts reached a consensus to adopt the term C3 glomerulopathy (C3G) to define a group of rare kidney diseases driven by dysregulation of the alternative complement pathway, mediated by geneticRead More…
The complement system, also known as the complement cascade, is a crucial component of both the innate and the adaptive immune systems, which can assist or supplement antibodies and phagocytes to clearRead More…
On April 28, AstraZeneca released news that its subsidiary Alexion’s new drug Ultomiris (Ravulizumab) was approved by the FDA for the treatment of anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) adultRead More…
According to statistics, the prevalence of atypical hemolytic uremic syndrome (aHUS) is about seven in one million. The majority of aHUS have complement-related factor gene mutations, and the etiology of about 6%Read More…